Guggenheim Begins Coverage on Sionna Therapeutics (NASDAQ:SION)

Equities researchers at Guggenheim began coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $45.00 price target on the stock. Guggenheim’s target price indicates a potential upside of 212.28% from the stock’s current price.

Sionna Therapeutics Price Performance

Shares of SION opened at $14.41 on Tuesday. Sionna Therapeutics has a one year low of $13.20 and a one year high of $25.19.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.